| Bioactivity | DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases[1]. |
| Invitro | DOTA-Zoledronate is a promising agent for the development of other future-oriented radionuclide therapy concepts for personalized nuclear oncology[1]. |
| Name | DOTA Zoledronate |
| CAS | 1908409-18-6 |
| Formula | C23H41N7O14P2 |
| Molar Mass | 701.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. The ITM Group Announces In-Licensing of DOTA-Zoledronate Theranostic Agent. |
DOTA Zoledronate
CAS: 1908409-18-6 F: C23H41N7O14P2 W: 701.56
DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.